Clinical review 121: Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 1, 2001, Pages 16-23

  Santen, Richard J ^a   Pinkerton, Joann ^a   McCartney, Christopher ^a   Petroni, Gina R ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; GESTAGEN; RALOXIFENE; TAMOXIFEN;

BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; META ANALYSIS; MITOSIS INHIBITION; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; UTERUS; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; RISK FACTOR;

BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTINS; RISK FACTORS;

EID: 0035221104     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.1.16     Document Type: Review

References (69)

1. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
2. Effect of hormone replacement therapy on breast cancer risk: Estrogen vs. estrogen plus progestin
3. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy
4. Prevention of spontaneous tumors in female rats by fadrozole hydrochloride, an aromatase inhibitor
5. Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen
6. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
7. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
8. Breast cancer and artificial menopause: A cohort study
9. Menopause and breast cancer risk
10. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
11. The effect of raloxifene on risk of breast cancer in postmenopausal women; results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
12. Epidemiological evidence for the increased cell proliferation model of carcinogenesis
13. Role of progestogens in the prevention of breast cancer
14. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles
15. Contraception
16. Androgenic, antiandrogenic, and synandrogenic actions of progestins: Role of steric and allosteric interactions with androgen receptors
17. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism
18. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 β-hydroxysteroid dehydrogenase activity
19. Opposite effects of estrogen and progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells
20. The estrogenic activity of synthetic progestins used in oral contraceptives
21. Proapoptotic effects of antiestrogens, progestins, and androgen in breast cancer cells
22. Effects of progestins on growth of experimental breast cancer in culture: Interaction with estradiol and PRL and involvement of the polyamine pathway
23. Progestin stimulation of thymidine kinase in the human breast cancer cell line T47D
24. Mechanisms of growth inhibition by antiestrogens and progestins in human breast and endometrial cancer cells
25. Mechanisms of cyclin-dependent kinase inactivation by progestins
26. Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: An in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids
27. Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists
28. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions
29. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals
30. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways
31. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity
32. Oral contraceptive use influences resting breast proliferation
33. The effect of age and menstrual cycle upon proliferative activity of the normal human breast
34. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo
35. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast
36. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
37. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
38. The effect of hormone replacement therapy on the sensitivity of screening mammograms
39. Mammographic breast density during hormone replacement therapy: Differences according to treatment
40. Effect of estrogen and estrogenprogestin replacement regimens on mammographic breast parenchymal density
41. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone
42. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
43. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women
44. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long term follow-up of a Swedish cohort
45. Hormone replacement therapy and the risk of breast cancer. Nested case control study in a cohort of Swedish women attending mammography screening
46. Estrogen replacement therapy and the risk of breast cancer: Results from the case-control surveillance study
47. Influence of noncontraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark
48. Menopausal hormone usage and breast cancer in Saskatchewan: A record-linkage cohort study
49. Breast cancer risk after estrogen replacement therapy: Results from the Toronto Breast Cancer Study
50. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
51. Incidence of breast cancer in a 22-year study of women receiving estrogenprogestin replacement therapy
52. Noncontraceptive hormone use and risk of breast cancer
53. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy
54. Relative vs. attributable risk of breast cancer from estrogen replacement therapy
55. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
56. Randomized trial of estrogen and progestin for secondary prevention of coronary heart disease in postmenopausal women
57. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
58. Estrogen tied to slight increase in risks to heart, a study hints (newspaper report of letter sent to study participants by the study coordinators)
59. Estrogen replacement therapy and breastcancer survival in a large screening study
60. Alternatives to the use of estrogen in postmenopausal women
61. Venlafaxine alleviates hot flashes: An NCCTG trial
62. Preliminary evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors
63. Stimulation of bone formation in vitro and in rodents by statins
64. Statin use, bone mass, and fracture: An analysis of two prospective studies
65. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
66. HMG-CoA reductase inhibitors and the risk of fractures
67. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
68. Do statins prevent both cardiovascular disease and fracture?
69. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women